Research programme: cancer therapeutics - Angiotech/Sanofi Genzyme
Latest Information Update: 20 Dec 2016
At a glance
- Originator Angiotech Pharmaceuticals; Genzyme Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 May 2006 Early research in Cancer in USA and Canada (Parenteral)